# Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

> **NCT05286164** · PHASE2 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- CART Treatment
- B Cell Lymphoma

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT05286164
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2023-04
- **Final completion:** 2024-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286164, "Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05286164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*